Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21119266 | 1.00 | OPRM1 (0.42) | OPRM1HTR2AAKR1C1CYP2D6HDAC1 | |
| SCHEMBL14232738 | 0.91 | OPRM1 (0.40) | OPRM1HTR2AAKR1C1HDAC1SSTR4 | |
| SCHEMBL11119002 | 0.84 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL11094114 | 0.83 | OPRM1 (0.60) | OPRM1 | |
| SCHEMBL11120120 | 0.81 | HTR2C (0.47) | OPRM1 | |
| SCHEMBL8105095 | 0.78 | AKR1C1 (0.46) | OPRM1AKR1C1CYP2D6MAOBALOX15 | |
| SCHEMBL12020309 | 0.78 | AKR1C1 (0.46) | OPRM1AKR1C1CYP2D6MAOBALOX15 | |
| SCHEMBL8107068 | 0.78 | AKR1C1 (0.46) | OPRM1AKR1C1CYP2D6MAOBALOX15 | |
| SCHEMBL5437376 | 0.77 | MAOB (0.47) | AKR1C1CYP2D6MAOB | |
| SCHEMBL11768776 | 0.77 | OPRM1 (0.47) | OPRM1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263093-A1 | S1P modulating agents | BIOGEN MA INC. | 2016-09-15 | — | — | US | disclosed |
| EP-0034415-B1 | 1-(CYCLOHEXYL OR CYCLOHEXENYL)-4-ARYL-4-PIPERIDINECARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-05-30 | — | — | EP | disclosed |
| US-4369184-A | ANTIHISTAMINES; HETEROCYCLIC NITRILES | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-18 | — | — | US | disclosed |
| EP-0034415-A1 | 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263093-A1 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | OPRM1 1054/4885HTR2A 355/4885AKR1C1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.